Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$117.6M
69M shares
52-week range
$1.01 – $7.80
11% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.56%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $106.0K | $0 | $0 | $0 | $1.2M | $1.5M | $1.4M |
| Gross profit | −$106.0K | $0 | $0 | $0 | −$1.2M | −$1.5M | −$1.4M |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $620.0K | $1.1M | $23.8M | $54.1M | $68.1M | $76.5M | $71.0M |
| Operating income | −$1.4M | −$1.9M | −$27.1M | −$68.3M | −$84.8M | −$97.7M | −$93.6M |
| EBITDA | −$1.2M | −$1.8M | −$27.1M | −$64.9M | −$77.4M | −$89.1M | −$88.2M |
| Net income | −$1.3M | −$1.9M | −$27.3M | −$69.1M | −$78.6M | −$90.0M | −$89.7M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -0.06 | -0.18 | -1.22 | -4.42 | -3.30 | -2.85 | -2.12 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $37M | $-1.11 | $-1.38–$-0.89 | 6 |
| 2027 | $5M | $-1.19 | $-1.81–$-0.75 | 6 |
| 2028 | $31M | $-1.06 | $-1.69–$-0.79 | 5 |
| 2029 | $33M | $-0.89 | $-0.89–$-0.89 | 1 |
Forward consensus · source: Financial Modeling Prep
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
www.pepgen.comNo one on the platform currently holds PEPG.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 56,800 | $100.5K |
No one on the platform has traded PEPG yet.
| $87M |
| — |
| CYBNCybin Inc. | $8.28 | +1.22% | $413M | — |
| ELTXElicio Therapeutics, Inc. | $4.00 | -0.00% | $76M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$PEPG hold lifted round about now would be beautiful
View on StockTwits ↗$PEPG Check out this really good video on what is happening here https://youtu.be/qSiABDoIPNg?si=uw5nYGQr3Owjl70T
View on StockTwits ↗$GERN $PMVP $PEPG slow Shixxx!! pathetic... i think it will move in June... Just hold
View on StockTwits ↗$PEPG should be interesting this week leading up to presentation starting wednesday with actual data on thursday. Sounds promising the way they have worded it!
View on StockTwits ↗$PEPG holding big bag here.. shix... pathetic shix.. but that is okay.. it will go back up.... Cant lose on this one
View on StockTwits ↗$PEPG updated its corporate presentation for the 15th International Myotonic Dystrophy Consortium.
View on StockTwits ↗$PEPG 07:04 on May. 21 2026 PepGen To Highlight Data From PGN-EDODM1 Program In Poster And Late-Breaking Oral Presentation At IDMC-15 #tradeideas
View on StockTwits ↗$PEPG " . . . from time to time", lol. To me, that translates to, "MASSIVE dilution is imminent, starting immediately."
View on StockTwits ↗$PEPG In at 1.64 for 10k shares. MOA looks good, data look good even if one single patients went the other way in the active, and safety signal is good. At this price it's a great bet, given the hold is nonsensical to me. Higher dose and more patients hopefully will strengthen the signal and minimize the variability among patients which is expected for some endpoints. This approach can work for DM2, too, which is an advantage over other modalities.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.